World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
22114
World Ranking
16243
National Ranking
8166

Overview

Robert J. Kreitman is affiliated with the National Cancer Institute in the United States. Their research contributions span multiple areas within medicine, with a significant focus on hematologic malignancies and immunological disorders. Kreitman has authored and co-authored numerous scientific papers contributing to the understanding and treatment of various blood cancers and immune system dysfunctions.

Their published work covers key fields of study including Medicine and Immunology and Microbiology. Specific subfields frequently addressed in their research include Genetics, Immunology, Pathology and Forensic Medicine, Molecular Biology, and Oncology.

Main topics explored in their work are:

  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Toxin Mechanisms and Immunotoxins
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research

Some of Kreitman's recent papers include:

  • "Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial," 2021, Journal of Hematology & Oncology
  • "Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia," 2020, Journal of Clinical Oncology
  • "Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries," 2022, Nature Genetics
  • "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study," 2022, Annals of Oncology
  • "Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial," 2023, Nature Medicine

Kreitman collaborates frequently with several notable co-authors. The most frequent collaborators are:

  • Evgeny Arons (26 collaborations)
  • Hong Zhou (13 collaborations)
  • Hao-Wei Wang (12 collaborations)
  • Constance M. Yuan (11 collaborations)
  • Mark Raffeld (10 collaborations)

The most common venues for Kreitman's publications include:

  • Blood (13 publications)
  • Leukemia (4 publications)
  • Leukemia & lymphoma / Leukemia and lymphoma (4 publications)
  • Journal of Clinical Oncology (3 publications)
  • Blood Advances (2 publications)

Best Publications

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • Immunotoxin Therapy of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

    Robert J. Kreitman;Wyndham H. Wilson;Karen Bergeron;Miranda Raggio

  • Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

    Robert J. Kreitman;Wyndham H. Wilson;Jeffrey D. White;Maryalice Stetler-Stevenson

  • Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

    Raffit Hassan;Susie Bullock;Ahalya Premkumar;Robert J. Kreitman

  • Immunotoxin Treatment of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Martin S. Tallman;Tadeusz Robak;Steven Coutre

  • Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

    Robert J. Kreitman;David R. Squires;Maryalice Stetler-Stevenson;Pierre Noel

  • Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

    Robert W. Rand;Robert J. Kreitman;Nicholas Patronas;Frederick Varricchio

  • Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

    Robert J. Kreitman;Ira Pastan

  • Immunotoxins in cancer therapy.

    Robert J Kreitman

  • Ablation of Cerebellar Golgi Cells Disrupts Synaptic Integration Involving GABA Inhibition and NMDA Receptor Activation in Motor Coordination

    Dai Watanabe;Hitoshi Inokawa;Kouichi Hashimoto;Norimitsu Suzuki

  • Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

    Robert J. Kreitman;Raffit Hassan;David J. FitzGerald;Ira Pastan

  • High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

    Joshua J Waterfall;Evgeny Arons;Robert L Walker;Marbin Pineda

  • Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Maryalice Stetler-Stevenson;Inger Margulies;Pierre Noel

  • Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

    Michael R. Grever;Omar Abdel-Wahab;Leslie A. Andritsos;Versha Banerji

  • Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions

    Yoram Reiter;Ulrich Brinkmann;Robert J. Kreitman;Sun-Hee Jung

  • Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

    Raffit Hassan;Andrew C. Miller;Elad Sharon;Anish Thomas

  • Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

    Robert J. Kreitman;Claire Dearden;Pier Luigi Zinzani;Julio Delgado

  • Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

    Liqiang Xi;Evgeny Arons;Winnifred Navarro;Katherine R. Calvo

Frequent Co-Authors

Ira Pastan
Ira Pastan Center for Cancer Research
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
David J. FitzGerald
David J. FitzGerald MRC Laboratory of Molecular Biology
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health
Raj K. Puri
Raj K. Puri US Food and Drug Administration
Mark Raffeld
Mark Raffeld National Institutes of Health
Tadeusz Robak
Tadeusz Robak Medical University of Lodz
Mark C. Willingham
Mark C. Willingham Wake Forest University
Byungkook Lee
Byungkook Lee National Institutes of Health
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medicine but seeking alternate pathways or additional qualifications, a range of online options are available. For those looking to start their careers quickly, fast track lpn programs provide a streamlined route into nursing, with flexible online coursework designed to help you enter the workforce faster.

For registered nurses aiming to specialize further, accelerated msn psychiatric np programs offer a rapid way to gain advanced mental health skills. These focused online programs are ideal for those passionate about psychiatric nursing and patient care.

Students interested in managing healthcare facilities or advancing into administration roles should consider a healthcare administration degree. Comparing healthcare administration degree cost is essential to make informed choices and minimize student debt.

For those pursuing graduate studies, finding the cheapest mha online programs can make a master’s degree more accessible and affordable. These programs can open doors to high-level leadership roles within the healthcare sector.

Best Scientists Citing Robert J. Kreitman

Trending Scientists

Recently Published Articles